Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fresenius Medical Care (FMS – Research Report), Solid Biosciences (SLDB – Research Report) and Merck & Company (MRK – Research Report).
Fresenius Medical Care (FMS)
Truist Financial analyst David S Macdonald maintained a Hold rating on Fresenius Medical Care on November 15 and set a price target of $24.00. The company’s shares closed last Friday at $19.73.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Fresenius Medical Care with a $24.00 average price target.
See today’s best-performing stocks on TipRanks >>
Solid Biosciences (SLDB)
In a report issued on November 15, Joseph Schwartz from Leerink Partners maintained a Hold rating on Solid Biosciences. The company’s shares closed last Friday at $2.57, close to its 52-week low of $1.81.
According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Solid Biosciences is a Moderate Buy with an average price target of $6.50, which is a 144.4% upside from current levels. In a report issued on November 10, Piper Sandler also assigned a Hold rating to the stock with a $8.00 price target.
Merck & Company (MRK)
In a report issued on November 15, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $130.00. The company’s shares closed last Friday at $101.75.
According to TipRanks.com, Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $126.18, implying a 23.7% upside from current levels. In a report issued on November 8, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $115.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FMS:
- Fresenius Medical upgraded to Buy from Hold at Societe Generale
- Fresenius Medical price target lowered to EUR 34 from EUR 46 at Deutsche Bank
- Fresenius Medical to sell Boston IVF fertility network, TRIO to IVI RMA
- Fresenius Medical price target raised to EUR 39 from EUR 38 at Barclays
- Fresenius Medical price target lowered to EUR 28 from EUR 32.10 at JPMorgan
